- Home
- GMAB vs SBAC Comparison
GMAB vs SBAC Comparison
Compare GMAB & SBAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- SBAC
- Stock Information
- Founded
- GMAB 1999
- SBAC 1989
- Country
- GMAB Denmark
- SBAC United States
- Employees
- GMAB N/A
- SBAC N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- SBAC Real Estate Investment Trusts
- Sector
- GMAB Health Care
- SBAC Real Estate
- Exchange
- GMAB Nasdaq
- SBAC Nasdaq
- Market Cap
- GMAB 17.4B
- SBAC 20.2B
- IPO Year
- GMAB N/A
- SBAC 1999
- Fundamental
- Price
- GMAB $31.32
- SBAC $194.42
- Analyst Decision
- GMAB Strong Buy
- SBAC Buy
- Analyst Count
- GMAB 6
- SBAC 15
- Target Price
- GMAB $40.40
- SBAC $239.87
- AVG Volume (30 Days)
- GMAB 1.8M
- SBAC 994.1K
- Earning Date
- GMAB 11-06-2025
- SBAC 11-03-2025
- Dividend Yield
- GMAB N/A
- SBAC 2.30%
- EPS Growth
- GMAB 132.41
- SBAC 25.44
- EPS
- GMAB 25.10
- SBAC 7.95
- Revenue
- GMAB $3,845,670,022.00
- SBAC $2,789,256,000.00
- Revenue This Year
- GMAB $24.92
- SBAC $6.84
- Revenue Next Year
- GMAB $15.97
- SBAC $2.41
- P/E Ratio
- GMAB $1.25
- SBAC $24.32
- Revenue Growth
- GMAB 29.57
- SBAC 4.82
- 52 Week Low
- GMAB $17.24
- SBAC $185.45
- 52 Week High
- GMAB $33.65
- SBAC $245.16
- Technical
- Relative Strength Index (RSI)
- GMAB 63.22
- SBAC 46.40
- Support Level
- GMAB $29.98
- SBAC $191.97
- Resistance Level
- GMAB $30.82
- SBAC $198.39
- Average True Range (ATR)
- GMAB 0.65
- SBAC 4.06
- MACD
- GMAB 0.15
- SBAC -0.32
- Stochastic Oscillator
- GMAB 94.93
- SBAC 15.37
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About SBAC SBA Communications Corporation
SBA Communications owns a portfolio of about 45,000 wireless towers throughout North America, South America, and Africa. It leases space on its towers to wireless service providers, who install equipment to support their wireless networks. The company has a very concentrated customer base, with most revenue in each market being generated by the top few mobile carriers. It owns more than 17,000 towers in the US, which account for about 75% of leasing revenue. Internationally, SBA's largest presence is in Brazil, where it owns roughly 10,000 towers. SBA operates as a real estate investment trust.